Synergistic Effect of Curcumin on Controlling Irritative Urinary Symptoms After Benign Prostatic Enlargement Endoscopic Surgery Compared with Anticholinergic Therapy Alone

Introduction: Benign prostatic hyperplasia is a common condition in older males that causes bothersome symptoms. The purpose of this study is to evaluate the combined impact of curcumin and anticholinergic therapy in managing urinary irritation symptoms in patients with benign prostatic hyperplasia following prostate surgery.Methods: This randomized clinical trial included patients with benign prostate hyperplasia who experienced irritating symptoms after prostate surgery at Imam Reza Hospital in Mashhad from ۲۰۱۹–۲۰۲۰. Participants completed the IPSS questionnaire before the operation and were then classified into two groups. One group received anticholinergic therapy, and the other group received anticholinergic therapy plus curcumin BID for one month. The IPSS was used again at the end of one month, and results were analyzed using SPSS statistical software.Results: ۸۰ participants were included in this research, with an average age of ۶۳.۴±۱۳.۵ years in the control group and ۶۴.۶±۹.۵ years in the intervention group. Before the intervention, scores for urinary frequency (P-value=۰.۳۳۳), urinary urgency (P-value=۰.۳۸۷), nocturia (P-value=۰.۸۰۷), and total urinary symptom score (P-value=۰.۰۶۱) differed between the two groups. However, after the study, the intervention group had significantly lower scores for urinary frequency, urinary urgency, and total urinary symptom score compared to the control group (P-value<۰.۰۵). No significant difference was between two groups considering nocturia (P-value=۰.۰۵۱).Conclusion: This investigation was one of the first randomized clinical trials to evaluate curcumin's effects on reducing symptoms of benign prostatic hyperplasia. The results indicated that curcumin positively impacted decreasing these symptoms, although changes in nocturia were not significant.

Keywords:

benign prostatic hyperplasia , curcumin , lower urinary tract symptoms , Alpha-Blockers , ۵-alphareductase inhibitors